Stockscreener 앱 받기
1.26
4.55%
-0.06
시간 외 거래:
1.26
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference - Business Wire
Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday - Defense World
Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Quince Therapeutics (NASDAQ:QNCX) Price Target Lowered to $4.00 at D. Boral Capital - Defense World
Quince Therapeutics Reports 2024 Financial Results and Trial Progress - TipRanks
Quince Therapeutics stock target cut to $4 from $12, maintains buy By Investing.com - Investing.com South Africa
Quince Therapeutics stock target cut to $4 from $12, maintains buy - Investing.com
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Oppenheimer - Defense World
Quince Therapeutics Existing Cash Position To Provide Operating Runway Through Phase 3 Topline Results Into 2026 - MarketScreener
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
Oppenheimer sets $10 target for Quince Therapeutics stock By Investing.com - Investing.com South Africa
Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Quince Therapeutics at Outperform -March 24, 2025 at 07:46 am EDT - Marketscreener.com
Oppenheimer sets $10 target for Quince Therapeutics stock - Investing.com
Quince Advances Rare Disease Drug Trial with FDA Fast Track Status, $40M War Chest - Stock Titan
Quince Therapeutics (QNCX) Projected to Post Earnings on Monday - Defense World
Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $9.50 - Defense World
Quince Therapeutics (NASDAQ:QNCX) versus IN8bio (NASDAQ:INAB) Critical Contrast - Defense World
Market Momentum Report: Quince Therapeutics Inc (QNCX)’s Negative Close at 1.41 - The Dwinnex
Vaxart (NASDAQ:VXRT) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Comparison - Armenian Reporter
Ataxia Treatment Market Size in the 7MM is expected to grow - openPR
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
Head to Head Comparison: Quince Therapeutics (NASDAQ:QNCX) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Spotlight On Fractyl Health And Two Other Intriguing Penny Stocks - Simply Wall St
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average Price Target from Analysts - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
D. Boral Capital Reaffirms “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Quince Therapeutics secures USPTO nod for A-T treatment patent By Investing.com - Investing.com Australia
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Earnings Coming in Better-Than-Expected As Peak Season Begins - The Globe and Mail
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Meta Platforms Is Surging on Q4 Earnings. Is Meta Stock a Buy, Sell, or Hold for 2025? - The Globe and Mail
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average PT from Brokerages - Defense World
Earnings To Watch: Kirby (KEX) Reports Q4 Results Tomorrow - The Globe and Mail
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Marketscreener.com
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board - Business Wire
BioXcel Therapeutics expands board, appoints new director - Investing.com
Geode Capital Management LLC Purchases 66,170 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Average Target Price from Analysts - Defense World
Pharma Innovator Unlocks Multi-Disease Treatment Potential - Streetwise Reports
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics' (QNCX) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
1.23%
1.63%
자본화:
|
볼륨(24시간):